BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes

BridgeBio Pharma, Inc.

Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.
Net proceeds ~$619.3M; intended to repurchase, settle, or repay at maturity the 2.50% 2027 notes.
Concurrent $82.5M share repurchase: 1,081,825 shares at $76.26/share from note purchasers.
Initial conversion price ~$110.58/share, a ~45% premium over Jan 15 close of $76.26.
Notes are senior unsecured; redemption permitted after Feb 6, 2030 if stock >=130% of conversion price.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BridgeBio Pharma, Inc. incurred convertible notes of $632.5 million aggregate principal amount with qualified institutional buyers at 0.75% per year maturing February 1, 2033.

Instrument: convertible notes
Principal: $632.5 million aggregate principal amount
Counterparty: qualified institutional buyers
Rate: 0.75% per year
Maturity: February 1, 2033
Event: incurrence

Exact text from the filing

BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

BridgeBio Pharma, Inc. entered into 0.75% Convertible Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $632,500,000 aggregate principal amount (effective 2026-01-21).

Action: entry
Agreement: notes offering
Counterparty: U.S. Bank Trust Company, National Association
Value: $632,500,000 aggregate principal amount
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-001843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.